rimonabant

Phase 3Small molecule

rimonabant is a small molecule that works as a Cannabinoid CB1 Receptor Antagonist.[2] It is being investigated across 19 indications, with its most advanced program in Phase 3.[1]

rimonabant is one of 431 small molecule programs targeting Hepatic steatosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

430

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatic SteatosisActive, not recruiting

Metabolic SyndromeActive, not recruiting

Disorder of Lipid MetabolismActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Nicotine DependenceActive, not recruiting

HepatitisActive, not recruiting

Prader-Willi SyndromeActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

AtherosclerosisActive, not recruiting

Coronary AtherosclerosisActive, not recruiting

Hepatic SteatosisPhase 3

Active, not recruiting

Metabolic SyndromePhase 3

Active, not recruiting

Disorder of Lipid MetabolismPhase 3

Active, not recruiting

Cardiovascular DiseasePhase 3

Active, not recruiting

Nicotine DependencePreclinical

Active, not recruiting

HepatitisPhase 3

Active, not recruiting

Prader-Willi SyndromePhase 3

Active, not recruiting

Type 2 Diabetes MellitusPhase 3

Active, not recruiting

AtherosclerosisPhase 3

Active, not recruiting

Coronary AtherosclerosisPhase 3

Active, not recruiting

Showing 10 of 18 indications

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

rimonabant

Sanofi

Phase 3

7 2

Jardiance

Boehringer Ingelheim

Preclinical

31 3

NOVOLIN R

Novo Nordisk

Preclinical

5 4

Cysteine Hydrochloride

Novartis

Preclinical

1 5

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 6

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 7

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 8

Lovaza

AstraZeneca

Preclinical

1 9

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 10

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes7 trials

A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00449605·508 enrolled

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00577148·89 enrolled

REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents

Completed· Sanofi logo

Sanofi·Phase 3·NCT00546325·358 enrolled

Show 4 more trials

Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00325650·2,420 enrolled

Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00690456·403 enrolled

Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes

Withdrawn· Sanofi logo

Sanofi·Phase 3·NCT00754689

Obese Patients With Type 2 Diabetes

Completed· Sanofi logo

Sanofi·Phase 3·NCT00029848·1,045 enrolled

Obese Patients7 trials

European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00412698·645 enrolled

Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00405808·2,666 enrolled

Japanese Dose-Response Study of Rimonabant in Obese Patients

Completed· Sanofi logo

Sanofi·Phase 2·NCT00459004·527 enrolled

Show 4 more trials

An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients

Completed· Sanofi logo

Sanofi·Phase 3·NCT00239967·803 enrolled

Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00434096·915 enrolled

Obese Patients With or Without Comorbidities (RIO-North America)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00029861·3,045 enrolled

Obese Patients With Untreated Dyslipidemias

Completed· Sanofi logo

Sanofi·Phase 3·NCT00029835·1,033 enrolled

Smoking Cessation5 trials

Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus Placebo in Smoking Cessation

Completed· Sanofi logo

Sanofi·Phase 3·NCT00464165·789 enrolled

Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation

Completed· Sanofi logo

Sanofi·Phase 3·NCT00464256·533 enrolled

Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00358228·787 enrolled

Show 2 more trials

Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch

Completed· Sanofi logo

Sanofi·Phase 3·NCT00458718·755 enrolled

Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation

Completed· Sanofi logo

Sanofi·Phase 3·NCT00459173·4,850 enrolled

Type 2 Diabetic Patients2 trials

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00478595·458 enrolled

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00478972·321 enrolled

Atherosclerosis2 trials

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00228176·661 enrolled

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00124332·839 enrolled

18 more indications

Spinal Cord Injury2 trials

Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

Completed·—·Phase 1/2·NCT05398913·8 enrolled

Effects of CB1 Antagonist/Reverse Agonist Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

Unknown status·—·Phase 2·NCT05622994·80 enrolled

Obesity2 trials

Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00386061·1,507 enrolled

Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00325546·643 enrolled

Efficacy2 trials

Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients

Completed· Sanofi logo

Sanofi·Phase 3·NCT00257257·281 enrolled

Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00288236·368 enrolled

Atherosclerotic Plaque1 trial

Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque

Completed·—·N/A·NCT00636766·300 enrolled

Cardiovascular Disease1 trial

Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.

Unknown status·HHospital Arnau de Vilanova·Phase 4·NCT00734123·2,948 enrolled

Cardiovascular1 trial

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00263042·18,695 enrolled

Prader-Willi syndrome1 trial

Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome

Terminated·WWeill Medical College of Cornell University·Phase 3·NCT00603109·10 enrolled

Cannabis Dependence1 trial

Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults

Completed·TThe Scripps Research Institute·Phase 2·NCT00656487·66 enrolled

Fat Metabolism1 trial

The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition

Terminated·UUniversity of Surrey·Phase 4·NCT00584389·14 enrolled

ESS1 trial

VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt

Completed· Sanofi logo

Sanofi·Phase 3·NCT00299325·254 enrolled

Hepatitis1 trial

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00576667·165 enrolled

Withdrawal1 trial

Antagonist-Elicited Cannabis Withdrawal

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 1·NCT01041170

Lip1 trial

High Density Lipoprotein Turnover

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00408148·64 enrolled

Cardiovascular Risk Factor1 trial

Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00458081·174 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese Patients

Completed· Sanofi logo

Sanofi·Phase 3·NCT00481923·156 enrolled

Overweight1 trial

Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00678483·331 enrolled

Weight loss1 trial

Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients

Completed· Sanofi logo

Sanofi·Phase 3·NCT00481975·289 enrolled

Unspecified1 trial

The Effects of Rimonabant, on Weight and Metabolic Risk Factors

Terminated·UUniversity of Maryland, Baltimore·Phase 2·NCT00547118·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 44 trial records for rimonabant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rimonabant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rimonabant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cannabinoid CB1 Receptor Antagonist[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

rimonabant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes7 trials

Obese Patients7 trials

Smoking Cessation5 trials

Type 2 Diabetic Patients2 trials

Atherosclerosis2 trials

Spinal Cord Injury2 trials

Obesity2 trials

Efficacy2 trials

Atherosclerotic Plaque1 trial

Cardiovascular Disease1 trial

Cardiovascular1 trial

Prader-Willi syndrome1 trial

Cannabis Dependence1 trial

Fat Metabolism1 trial

ESS1 trial

Hepatitis1 trial

Withdrawal1 trial

Lip1 trial

Cardiovascular Risk Factor1 trial

Efficacy and Safety1 trial

Overweight1 trial

Weight loss1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News